Yes, I believe that would give them more competitive advantage...It also would likely bring in the Justice department on an already existing monopoly that's costing the federal and state governments BILLIONS...And increase the pressure to bring Omontys back.
FWIW, as an M&A guy I do NOT see that happening as anything but remote at this time.
It's a lunch time beauty and another good article don't you know with much veracity. A prior article was on UNXL around $15 too and that one has touched $20 just as we speak. Shortie is not liking this one bit IMHO.
As it goes for RMTI, the medical community will most notably embrace the new SFP iron drug with open arms and save a bunch of capital at Medicare. #1 DaVita is also a very large customer too I believe.
You must believe that the med funds will eat this stock up on this most favorable Cruise data today, and $6.00 is very cheap.
Possibly replay the CC for more pertinent info if you so desire fellows.
Sentiment: Strong Buy